- Molecular NameMaprotiline
- SynonymMaprotilina [INN-Spanish]; Maprotiline Hcl; Maprotilinum [INN-Latin]; Maprotylina [Polish]
- Weight277.411
- Drugbank_IDDB00934
- ACS_NO10262-69-8
- Show 2D model
- LogP (experiment)4.85
- LogP (predicted, AB/LogP v2.0)5.05
- pka10.5
- LogD (pH=7, predicted)2.04
- Solubility (experiment)Slightly soluble
- LogS (predicted, ACD/Labs)(ph=7)-1.35
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.06
- No.of HBond Donors1
- No.of HBond Acceptors1
- No.of Rotatable Bonds4
- TPSA12.03
- StatusFDA approved
- AdministrationN/A
- PharmacologyA tetracyclic antidepressant (TeCA). It is a strong norepinephrine reuptake inhibitor with only weak effects on serotonin and dopamine reuptake.
- Absorption_value98.0
- Absorption (description)Slowly but completely absorbed following oral administration.
- Caco_2N/A
- Bioavailability68.0
- Protein binding90.0
- Volume of distribution (VD)23 to 70 L/kg (mean 52)
- Blood/Plasma Partitioning ratio (D_blood)Blood : plasma ratio, 1.7. However, the plasma:whole blood ratio has been reported to vary between individuals and may also vary between single and multiple dosing [K. P. Maguire et al.,Eur. J. Clin. Pharmacol.,1980, 18, 249–254].
- MetabollsmIt appears to undergo significant first-pass metabolism.
- Half life45 h
- ExcretionAfter oral administration, about 66% of a dose is excreted in the urine and 30% in the faeces over a period of 21 days; less than 10% of the dose is excreted as unchanged drug. The principal metabolite is the desmethyl derivative, which has been shown to be active in animals, but hydroxylation also occurs to form phenolic derivatives which may be further converted to aromatic methoxy ethers or excreted as glucuronide conjugates; N-oxidation also occurs and maprotiline N-oxide has been reported to be active; numerous minor metabolites have been identified in urine.
- Urinary ExcretionN/A
- Clerance15 ml/min/kg
- ToxicitySigns of overdose include motor unrest, muscular twitching and rigidity, tremor, ataxia, convulsions, hyperpyrexia, vertigo, mydriasis, vomiting, cyanosis, hypotension, shock, tachycardia, cardiac arrhythmias, impaired cardiac conduction, respiratory depression, and disturbances of consciousness up to deep coma.
- LD50 (rat)LD50=~900 mg/kg
- LD50 (mouse)N/A